Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02549937 · ClinicalTrials.gov registry record · Phase 1
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
A Phase 1 study of Tumors, sponsored by Hutchmed.
- Completed
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
- 12
- Study locations
NCT02549937 is a Phase 1 study of Tumors that has completed, run by Hutchmed. The registered enrollment target is 130 participants, below the 193-participant average among 20 other Tumors trials with a reported enrollment target (33% lower). The trial reports 12 study locations across 8 states.
The verdict
NCT02549937, a Phase 1 study of Tumors, has completed, sponsored by Hutchmed.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
- 12
- Study locations
Study Summary
Primary Objective Dose Escalation: To evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D). Primary Objective Dose Expansion: To evaluate the anticancer activity of surufatinib in patients with advanced Biliary Tract Cancer (BTC), patients with advanced pancreatic neuroendocrine tumors (pNETs), patients with locally advanced, unresectable, metastatic extra-pancreatic neuroendocrine tumors (EP-NETs), and patients with soft tissue sarcomas (STS) treated at a dose of 300 mg QD. Secondary Objective: To evaluate the pharmacokinetic profile of multiple dose surufatinib in patients with advanced solid tumors and to evaluate the anti cancer activity of surufatinib in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG surufatinib
Study Locations (12)
Texas
- Mary Crowley Cancer Research Center - Dallas
- Baylor Charles A. Sammons Cancer Center - Dallas
- MD Anderson Cancer Center - Houston
Colorado
- Rocky Mountain Cancer Center - Denver
- SCRI at HealthONE - Denver
New York
- Mount Sinai Hospital - New York
- Memorial Sloan Kettering Cancer Center - New York
California
- City of Hope Comprehensive Cancer Center - Los Angeles
Florida
- Florida Cancer Specialists - Sarasota
Tennessee
- Tennessee Oncology - Nashville
Virginia
- Virginia Cancer Specialists, PC - Fairfax
Other
- Fondazione IRCCS Istituto Nazionale dei Tumori - Milan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2015-11 |
| Est. Completion | 2023-06-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02549937
The ClinicalTrials.gov registry entry for NCT02549937 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 20 other Tumors trials with a reported enrollment target (33% lower). The listed sponsor is Hutchmed, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tumors appearing as the primary indexed condition, and to 1 intervention - of which surufatinib is the first listed.
NCT02549937 reports 12 study locations spanning 8 distinct geographic areas - top geographies include Texas, Colorado, New York.
Frequently Asked Questions
What is clinical trial NCT02549937 about?
NCT02549937 is a clinical study titled "A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors". Primary Objective Dose Escalation: To evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D). Primary Objective Dose Expansion: To evaluate the anticancer activity of surufati...
What is the current status of trial NCT02549937?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2015-11. Estimated completion is 2023-06-02.
What conditions does trial NCT02549937 study?
This clinical trial studies the following conditions: Tumors.
What interventions are being tested in trial NCT02549937?
The interventions under investigation include: surufatinib (DRUG).
Who is sponsoring clinical trial NCT02549937?
This trial is sponsored by Hutchmed, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02549937 being conducted?
This trial has 12 study locations across California, Colorado, Florida, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
HP Pyruvate MRI in Cancers
RECRUITING · Phase 1
-
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
COMPLETED · Phase 1
-
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
COMPLETED · Phase 1
-
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
COMPLETED · Phase 1
-
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.